STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

APLS Form 144 Filed for 189-Share Sale from Vested Restricted Stock

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Apellis Pharmaceuticals, Inc. (APLS) Form 144 notice reports a proposed sale of 189 shares of common stock held at Fidelity Brokerage Services with an aggregate market value of $4,572.29. The shares, part of restricted stock that vested on 09/12/2025, were acquired from the issuer as compensation and the filer plans an approximate sale date of 09/15/2025 on NASDAQ. The filing also discloses that the same account sold 548 shares on 09/02/2025 for gross proceeds of $15,386.20. These amounts are small relative to the reported 126,289,910 shares outstanding, and the filer represents no undisclosed material adverse information.

Positive

  • Full Rule 144 disclosure provided including acquisition date, nature of acquisition, broker, planned sale date, and prior sales
  • Insider attestation present stating no undisclosed material adverse information

Negative

  • None.

Insights

TL;DR: Routine insider sale from vested restricted stock; immaterial to overall share base.

The filing indicates a small, scheduled sale of vested restricted common stock: 189 shares valued at $4,572.29, with a recent prior sale of 548 shares for $15,386.20. Given the issuer's stated 126,289,910 shares outstanding, these transactions represent a negligible percentage of the float and are typical of insiders monetizing small vested awards for liquidity. The filing includes the standard attestation about absence of undisclosed material information.

TL;DR: Disclosure aligns with Rule 144 requirements; no governance red flags from this notice alone.

This Form 144 provides required details: acquisition date (09/12/2025), nature (restricted stock vesting), planned sale date (09/15/2025), broker, and historical sales in the past three months. The signatures/attestations included are standard. There is no indication in the document of irregular trading plans or undisclosed material information, and the transaction sizes are immaterial versus total shares outstanding.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Apellis (APLS) Form 144 report?

The notice reports a proposed sale of 189 shares of common stock (aggregate market value $4,572.29) acquired via restricted stock vesting on 09/12/2025.

When are the shares expected to be sold?

The filing lists an approximate sale date of 09/15/2025 on NASDAQ.

How many shares has the filer sold recently?

The filer sold 548 shares on 09/02/2025 for gross proceeds of $15,386.20.

Who is the broker handling the proposed sale?

Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield RI 02917

How material is this sale relative to Apellis outstanding shares?

Materiality is low: 189 shares versus 126,289,910 shares outstanding as reported in the filing.
Apellis Pharmace

NASDAQ:APLS

APLS Rankings

APLS Latest News

APLS Latest SEC Filings

APLS Stock Data

2.61B
106.61M
13.68%
105.74%
16.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM